Slides
Page 1
Building Growth Momentum Toward 2030 Goals Evotec Third Quarter and First Nine Months 2026 Results November 5, 2026
Page 2
PAGE 2 Today’s Speakers Christian Wojczewski CEO Business Update Claire Hinshelwood CFO Financial Update
Page 3
PAGE 3 Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection here with or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Section 5(d)and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutiona l accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of a ny such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither theCompany nor any of its directors, officers, employees, affiliates, agents, a dvisors or representatives shall have any liability relating thereto. Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as wel l as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying wor ds. Forward-looking statements are based on our management’s beliefs and assump tions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of newinformation or future developments or to release publicly any revisions tothese statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.
Page 4
PAGE 4 Third Quarter and First Nine Months Highlights Stronger execution with improving commercial and financial momentum CER: Constant exchange rates • Strong Q3 performance y-o-y €164.9 m Group revenue, -€1.6 m adj. EBITDA • 9M D&PD base-business net sales up 24% y-o-y Positive commercial momentum confirmed • JEB advances toward commercial scale Vertex selects JEB for manufacturing of povetacicept • Horizon execution ahead of plan >20% of €75 m run rate cost-out target delivered YTD • FY 2026 guidance reaffirmed Revenue and adj. EBITDA expected at upper end of ranges • 2030 framework Greater visibility on future business mix 9M 2026 GROUP REPORTING Group revenue €465.0 m €477.4 m CER R&D expenses €29.7 m (6.4% of revenue) Adj. group EBITDA -€44.3 m -€39.1 m CER 9M 2026 SEGMENT REPORTING D&PD Revenues €348.0 m Adj. EBITDA -€25.5 m JEB Revenue €117.1 m Adj. EBITDA -€18.8 m
Page 5
PAGE 5 Improving Evotec’s Scientific Profile Evotec welcomed new Chief Scientific Officer on November 1, 2026 Dr. Joanna Holbrook Chief Scientific Officer Background 2022 – 2026 Novo Nordisk Therapy Area Head, CVR & Hepatic Disease; Head of in vitro Discovery Platforms Prior: Biomodal : Chief Scientific Officer BenevolentAI : VP Translational Medicine Academic & Pharma Career University of Southampton, A*STAR Singapore, GSK University College London PhD, Molecular cell biology Mandate & Priorities 01 Strengthen scientific profile 02 Advance data- and AI- enabled discovery 03 Focus innovation on value creation
Page 6
PAGE 6 Differentiated Platforms Drive Progress in Partnerships Ramping up commercial readiness in JEB and expanding partnerships in cutting-edge science Discovery & Preclinical Development Just – Evotec Biologics N E W Selected by Vertex for commercial manufacturing of povetacicept Manufacturing at J.POD ® Redmond, leveraging proprietary continuous manufacturing platform Anchors utilization of planned capacity expansion S EP 2 0 2 6 DoW Orthopoxvirus antibody program advanced into Ph1 Program advanced from sequence to cGMP clinical supply Jazz Pharmaceuticals AI collaboration AI-enabled sleep disorder candidate entered Ph1 S EP 2 0 2 6 Plectonic Research collaboration Next-gen T cell engaging approaches in solid tumors A U G 2 0 2 6 Odyssey Therapeutics AI collaboration AI-enabled R&D in autoimmune & inflammatory diseases N EW DoW: U.S. Department of War
Page 7
PAGE 7 Nine months ended Sept 30, Three months ended Sept 30, Change 2025 2026 Change 2025 2026 in € m 1 -13.1% 535.1 465.0 0.6% 163.9 164.9 External Revenues -11.2% 391.9 348.0 -2.3% 122.9 120.1 D&PD -18.3% 143.2 117.1 9.4% 41.0 44.8 JEB -7.1 ppts 10.7% 3.6% 7.9 ppts 4.1% 12.0% Gross margin -5.6 ppts 13.6% 8.0% 4.9 ppts 9.9% 14.7% D&PD -12.3 ppts 2.7% -9.5% 17.8 ppts -13.1% 4.7% JEB 29.8% -42.3 -29.7 27.3% -12.8 -9.3 R&D expense -162.4% -16.9 -44.3 89.1% -15.0 -1.6 Adj. Group EBITDA 2 -35.3% -18.8 -25.5 89.1% -9.5 -1.0 D&PD n.m. 1.9 -18.8 89.2% -5.5 -0.6 JEB Condensed Income Statement Third Quarter and First Nine Months 2026 1 Differences may occur due to rounding 2 Adjusted EBITDA excludes changes of contingent consideration, impairments on intangible and tangible assets as well as the total non-operating result Q3 revenue broadly stable year-on-year, with stronger margins and adjusted EBITDA close to breakeven
Page 8
PAGE 8 Capital Discipline Supports Financial Flexibility Solid balance sheet and a sharply reduced CAPEX base Liquidity in € million 371 348 237 476 445 466 401 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Net debt / (net cash) in € m 107 114 246 (40) (10) 7 77 Capex in € million 118 73 19 2023 2024 2025 9M 2026 FY2026 CAPEX in % of revenue ~27% ~15% 9% 6% 213 Toulouse J.POD 19
Page 9
PAGE 9 Commercial Execution Translating into Business Traction Continued strong growth in net sales in D&PD base business * Net sales = work orders + positive change orders – negative change orders; numbers exclude major strategic partnerships D&PD Base Business net sales growth Incl. stand alone and integrated programs* ~24% 9M 2026 y-o-y growth vs. 9M 2025 Strategic Partnerships Near-term proof points of a healthy partnership pipeline ~20 opportunities in the partnership pipeline Customer Base ~10% vs. 9M 2025 Inbound Leads In D&PD base business >45% increase in # of leads ~20% improvement in turnaround time ~€1 bn total potential deal value
Page 10
PAGE 10 Horizon Delivery Ahead of Plan Savings accelerating as workforce, footprint and organizational measures advance >20% of ~€75 m target by Sep, ahead of 20-30% planned for FY26 ~50% of planned workforce measures implemented Pillar Progress in 2026 Status Operational Excellence Footprint consolidation advancing across Europe and in the U.S. On track Scientific Leadership Scientific capabilities being consolidated into focused Centers of Excellence On track Commercial Execution Commercial ramp up translating into stronger commercial funnel and net sales On track 3 of 4 site closures expected to be completed by end of 2026
Page 11
PAGE 11 Full-Year 2026 Guidance Confirmed Revenue and adj. EBITDA expected at the upper end of the respective ranges Group revenue FY 2026 guidance Expected: Upper end of range €570 m €610 m €595 to 635 m CER Adj. Group EBITDA FY 2026 guidance Expected: Upper end of range (lower loss) -€105 m -€70 m -€90 to -€60 m CER N i n e M o n t h s 2 0 2 6 €465.0 m Group revenue -€44.3 m Adj. Group EBITDA What supports delivery at the upper end Stronger commercial execution Robust D&PD base business contribution Horizon savings delivery CER: Constant exchange rates
Page 12
PAGE 12 Building a Structurally Stronger Business by 2030 2030 revenue mix combines a stronger base business with scalable, higher-margin growth Mid-range plan 2028 20% Adj. EBITDA margin 2030 ~€1 billion Revenue >20% Adj. EBITDA margin D&PD 60% JEB 40% Exp. share of revenue (2030) 40% Base business 20% Strategic partnerships 40% Just – Evotec Biologics Exp. gross margin range (2030) Increasing profitability and structurally stronger earnings profile Revenue upside potential >20% >+15 ppts on base business >30%
Page 13
PAGE 13 Distinct Growth Paths Build the 2030 Revenue Mix Clear drivers across the business combine to deliver the targeted 40/20/40 revenue mix *Illustrative, not to scale Base business growth • Market recovery & geographic expansion • Commercial execution • AI enabled partnerships JEB growth • Vertex & new customer ramp up • 3rd train capacity expansion • Higher-margin licensing growth Base Business ~€400 m ~10% CAGR Strategic Partnerships ~€200 m (risk adj.) ~5% CAGR Build • 3rd train installation Ramp-up • Vertex • new customers Acceleration • Licensing business • Royalty contribution ~€400 m ~20% CAGR FY2026 2030 Strategic Partnerships Range incl. upside D&PD* JEB* Strategic Partnerships growth • Risk-adj. progression of existing partnerships • New strategic partnerships • Partnering upside
Page 14
PAGE 14 Increased Forward Momentum Across Business Segments Third quarter shows clear progress toward mid-term goals • Commercial execution increasingly translating into business traction: 24% increase in D&PD net sales 9M year-over-year; progressing new strategic partnership opportunities. • Horizon moving from implementation into P&L impact: Savings ahead of plan, workforce measures and footprint consolidation on track. • JEB advancing toward commercial-scale manufacturing. • FY 2026 outlook reaffirmed: Revenue and adj. EBITDA expected toward upper end of respective ranges. • Mid-range framework detailed for future earnings profile: 20% adj. EBITDA margin by 2028; ~€1 bn revenue and >20% adj. EBITDA margin by 2030, based on a 40/20/40 revenue mix across base business, strategic partnerships and JEB.
Page 15
Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations sarah.fakih@evotec.com Thank you